United Therapeutics (UTHR) CEO sells 9,500 shares under 10b5-1 plan

robot
Abstract generation in progress

United Therapeutics (UTHR) CEO Martine Rothblatt exercised options for 9,500 shares and subsequently sold them in open-market transactions on March 30, 2026, under a pre-arranged 10b5-1 trading plan. The transactions involved exercising options at $146.03 per share and selling shares between approximately $581-$603, totaling a net sale of $5.61 million. This activity is considered routine diversification, with Rothblatt retaining substantial direct and indirect holdings in the company.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin